Latest version of Trial Accelerator™ incorporates new AI capabilities and product features to unlock a patient-centric approach to trial design and implementation
C. Ola Landgren and colleagues discuss adapting to a field transformed by new immunotherapy drugs and targeted therapies and how to best combine treatments
Two clinical trials testing loncastuximab tesirine in patients with high-risk follicular lymphoma or with rare, marginal zone lymphoma show encouraging results
Learn how clinical labs can leverage crowdfunding to reduce diagnostic test development costs and meet FDA LDT compliance requirements
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.